Overview of Could this nasal spray replace all your vaccines one day?
This NPR Short Wave episode explores a bold idea in immunology: a “universal vaccine” delivered as a nasal spray that could provide broad, temporary protection against many respiratory infections at once. Stanford immunologist Bali Pulendran explains how his team is trying to activate the innate immune system—the body’s ancient, broad-acting first line of defense—rather than relying only on highly specific antibodies and T-cells. In mice, the approach has shown protection against multiple viruses, bacteria, and even allergens, raising the possibility of a future stopgap vaccine for seasonal use or pandemic response.
The core scientific idea
Why current vaccines are limited
- Most vaccines target a single pathogen or a closely related group of pathogens.
- They work by training the adaptive immune system:
- Antibodies bind specific viruses or microbes.
- T-cells also recognize particular threats.
- This specificity is powerful, but it means vaccines usually need to be redesigned for new strains or new diseases.
The “older” immune system scientists are trying to harness
- Pulendran’s team focused on the innate immune system, described in the episode as the “Cinderella” of immunity because it has historically been overlooked.
- The innate immune system is:
- Ancient
- Broadly reactive
- Capable of rapidly responding to many different invaders
- Key cells include:
- Macrophages
- Dendritic cells
- Unlike antibodies, these cells are less selective and can rapidly engulf many kinds of pathogens.
How the nasal spray works
What’s in it
The experimental nasal spray contains two parts:
- Synthetic molecules that activate innate immune cells in the nose and lungs
- An antigen to help stimulate the immune response
What it did in mice
The treatment “supercharged” innate immune cells in the respiratory tract, helping them clear invaders quickly. In mouse studies, it provided protection for about three months against:
- Influenza
- SARS-related coronaviruses
- Other coronaviruses
- Staphylococcus aureus
- Other respiratory bacteria
- Allergens
Possible future uses
1. Seasonal broad protection
Pulendran imagines a future where people might use the spray during winter months to get broad, temporary protection against:
- Flu
- COVID-19
- RSV
- The common cold
This protection might last 3 to 6 months, based on the early research.
2. Pandemic stopgap
A more urgent use-case would be during the early stages of a new pandemic:
- A universal nasal spray could be deployed quickly
- It might reduce spread and severity while a pathogen-specific vaccine is still being developed
- This could buy valuable time during the first critical months of an outbreak
Where the research stands now
Current status
- The work has been demonstrated in mice only
- The next step is to prove it can work safely in humans
What’s needed before human use
Pulendran says the team is working toward:
- Fundraising for human studies
- Toxicology testing in animals such as rabbits
- Dose-escalation studies in humans
- Eventually, clinical challenge studies where volunteers would be vaccinated intranasally and exposed to influenza in a controlled setting
Timeline
- He estimates the team is roughly 3 to 4 years away from a human proof-of-concept study
- A widely available product is still much farther off
Main takeaways
- A universal vaccine may not replace all vaccines soon, but the research suggests a new direction for vaccine design.
- The strategy is fundamentally different from traditional vaccines because it aims to activate broad innate immunity, not just disease-specific adaptive immunity.
- The most promising near-term use may be as a temporary shield during flu season or the earliest phase of a pandemic.
- Safety remains the biggest hurdle, and Pulendran emphasizes that many stages of human testing will be required before this could become a real-world intervention.
Bottom line
This episode highlights an ambitious but still early-stage scientific vision: a nasal spray universal vaccine that could train the body’s innate immune defenses to fight a wide range of threats. The concept is promising, especially for respiratory infections and emergency pandemic response, but it remains years away from human use and will need extensive safety and efficacy testing before it can become reality.